Shaun is an experienced CNS drug discovery expert and biotechnology executive. He has over 25 years of industry experience in the neuroscience drug discovery units of major pharmaceutical company, including Parke-Davis, Pfizer and GSK, in contract research for Charles River, and as CSO for several biotechnology companies. Shaun has worked to develop a range of CNS targeted drugs including Neurontin and Lyrica, specialising now in drug development strategy and the successful transfer of drug candidates into clinical trials.
Shaun holds a D.Phil. in CNS cell signalling from the University of York and researched neurotransmitter-regulated pathways controlling circadian function and behaviour at the University of Cambridge, UK.
Dr. Shaun McNulty as been appointed Chief Scientific Officer in January 2021.
Sign Up for Newsletter
MAIN OFFICE
18 Dukes Road,
London WC1H 9PY, United Kingdom
© 2023 Awakn Life Sciences Corp | Privacy Policy | Appropriate Use Policy
